Sunday 11 October 2026 Export all SNY data to Excel Powerpack

Sanofi

SNY Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

40.07 0.16 −0.40%
Market cap
$95.9B
P/E
21.0×
Fwd P/E
—
Dividend yield
6.05%
F-score
7/9
Altman Z
2.50
Beneish M
−2.63
Dividend safety
58/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 7 — 6
ROE
0.00% 10.94% 0.00% 5.87%
ROA
7.01% 6.16% 6.06% 3.21%
ROIC
6.17% 6.57% 6.12% 6.58%
Return on Tangible Assets
75.08% 61.72% 72.55% 40.46%
Average Days of Receivables
4.53 68.81 3.75 68.60
Free Cash Flow per Share
0.00 7.62 0.00 6.08
Free Cash Flow
— 18,607.12 — 14,542.46
Other line items

Show all line items

Columns are period end dates